Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in ...
The feds intend to appeal a judge's decision that would force them to recalculate UnitedHealthcare's Medicare Advantage (MA) ...
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
The newly installed Trump administration late Tuesday prompted federal health agencies, including the Centers for Medicare & Medicaid Services (CMS), ...
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started ...
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
Providers are required by federal law to return Medicare and Medicaid overpayments within 60 days of identifying the ...
The Centers for Medicare and Medicaid Services will issue corrected data on Medicare Advantage enrollment the week of Jan. 20 ...
The General Enrollment Period provides an opportunity to make up for a past oversight – the failure to enroll in Part B.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback